Results of 30.06.2026.

Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com 30th July 2026 BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot no. Dalal Street, C/1, G Block, Bandra Kurla Complex, Mumbai – 400001 Bandra (East), Mumbai – 400 051 Scrip Code: BSE – AJANTPHARM 532331 Scrip Code: NSE AJANTPHARM EQ Sub.: Outcome of the Board Meeting Dear Sir/Madam, Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 30th July 2026, considered and approved the following: i. Unaudited Consolidated and Standalone Financial Results of the Company for the first quarter ended 30th June 2026. ii. 1st interim dividend for FY 2027. Each share of Rs. 2 face value will receive a dividend of Rs. 32, amounting to Rs. 400 cr. iii. Fixed Wednesday, 5th August 2026 as the Record date for payment of 1st interim dividend. Dividend will be paid on or after 18th August 2026. Please find enclosed herewith following: i. Press Release; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2026; iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the Unaudited Consolidated Financial Results for the quarter ended 30th June 2026; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2026; v. Limited Review Report from Auditors M/s B S R & Co. LLP on the Unaudited Standalone Financial Results for the quarter ended 30th June 2026; vi. Investor presentation. Meeting of the Board of Directors commenced at 1.30 p.m. and concluded at 2: 28 p.m. Kindly take the above on your records. Thanking You, Yours faithfully, GAURANG SHAH Sr. VP - Legal & Company Secretary Encl.: a/a Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com Press Release Revenue up by 25% and PAT up by 31% (1st Quarter FY 2027 Consolidated Results) Mumbai, 30th July, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 1st quarter ended 30th June 2026. Shareholders pay-out: Today Board of Directors have approved interim dividend of Rs. 32 per share for face value of Rs. 2 per share amounting to Rs. 400 cr. Q1 FY 2027 performance highlights (compared to Q1 FY 2026): • Revenue from operations at Rs. 1,626 cr. against Rs. 1,303 cr.; up 25%. • Adjusted EBITDA (excluding forex loss) at Rs. 454 cr. & 28% against Rs. 377 cr., up 21%. • Profit after tax at Rs. 334 cr. against Rs. 255 cr.; PAT at 21%; up 31%. • ROCE stood at a healthy level of 37% and RONW at 28%. Segment wise performance: (Rs. cr.) Markets Gwth% FY 2026 FY 2027 Branded Generics India ₹ 409 ₹ 509 24% Asia ₹ 304 ₹ 255 (16%) Africa ₹ 228 ₹ 295 30% Sub-Total ₹ 941 ₹ 1,059 13% US Generic ₹ 310 ₹ 487 57% Africa Institution ₹ 38 ₹ 70 83% Total ₹ 1,289 ₹ 1,616 25% As per IQVIA MAT June 2026, our India branded generic performance exceeded IPM growth by 36%. The higher growth came from new launches, which exceeded IPM by 76% & volumes, which exceeded IPM by 40%. Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com India branded generic Segment wise performance as per IQVIA MAT June 2026 against IPM is as below: Growth % Therapy IPM Ajanta Cardiology 15% 9% Ophthalmology 10% 15% Dermatology 8% 14% Pain Management 10% 15% Overall 11% 15% ANDA status as at the end of Q1 FY 2027 is as below: Particulars Q1 FY 2027 Filed - Approval received 3 Launched 2 Total ANDA's commercialized 51 Awaiting approval with US FDA 17 Tentative approval 5 R&D expense: (Rs. cr.) Particulars FY 2026 FY 2027 % to Revenue Q1 ₹ 56 ₹ 66 4% About Ajanta Pharma Limited Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 33+ countries. Many of company’s products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa. Company’s state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India. For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%. Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, T +91 22 6060 9000 Chakala, Andheri (E), E corpcom@ajantapharma.com Mumbai – 400 093, India W www.ajantapharma.com Earnings Conference Call The Company will host an Earnings Conference Call at 16:15 hrs. IST (18:45 hrs. SST/HKT, 11:45 hrs. BST, 06:45 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com. Dial-in Information Date and Time July 30, 2026 at 16:15 – 17:15 hrs IST 18:45 – 19:45 hrs SST/HKT 11:45 – 12:45 hrs BST 06:45 – 07:45 hrs US ET Dial-in Numbers Diamond pass link for faster access Click here to register Universal Access Primary Access: (+91 22 6280 1542) (+91 22 7115 8372) International Toll Free USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 For convenience and faster connectivity to the conference, kindly follow below steps: 1. Register through the Diamond pass link. 2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time. 3. Dial the ‘conference Dial-in number’ you will receive on your email. 4. On system prompt dial the PASSCODE followed by # key. 5. On system prompt enter the PIN followed by # key. 6. If the line gets disconnected, you need to dial the ‘conference dial-in number’ again and follow the necessary steps. Playback of Earnings Conference Call audio: Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com). For more details visit www.ajantapharma.com For regular updates follow us on x.com – https://x.com/AjantaPharmaLtd For specific queries, contact: Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331 Corporate Identity Number (CIN): L24230M9M979PLC022059 Safe Harbour Statement Corporate Identity Number - L24230MH1979PLC022059 Ajanta Pharma Limited ajanta pharma Ajanta Tower, 54-A, M V Road, T +91 2_2 6060 9000 Chakala, Andheri (E), E aplfinance@ajantapharma.com Mumbai - 400 093, India W www.ajantaphanna.com Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2026 l in Crore Particula~ 3 months ended Year Ended 30-Jun-26 31-Mar-2& 30-Jun-25 31-Mar-26 Unaudited Audited il!dcrM:i(e Jl Unaudited Audited Income -- Revenue rrom operations 1,625.96 1,421.64 1,302.65 5,452.86 Other income (Refer note 51 70.90 61.43 26.33 172.07 Total Income 1,696.86 1,◄83.07 1,328-98 5,624.93 Expenses Cost or materials consumed 296.51 256.76 207.08 916.51 Purchases of stock-in-trade - 66.92 71.35 -5-1.-63 229.79 Changes In lnventones of finished goods, worl<.-in-progress and stock-in-trade ( 35.58) (23.30) 17.17 -- 37.46 Employee benefits expense 381.11 340.72 302,90 1,291:!_5 Finance costs 3.18 2.36 5.26 16.11 Depreciation and amortisation expense ◄4.50 45.-37 41.29 173.14 Other expenses (Refer note 51 493.42 442.70 JTI.52 1,583.12 Total Expenses 1,250.06 1,135.96 997 [Showing first 8,000 characters — download PDF for full document]